Key result
Gpx1 deletion increases AngII-induced cardiac hypertrophy by ~21% and worsens systolic function in mice.
Why the study?
Does Glutathione Peroxidase 1 (Gpx1) deficiency accelerate cardiac and vascular hypertrophy, dysfunction, and hypertension in response to short-term angiotensin II infusion in mice?
Does Glutathione Peroxidase 1 (Gpx1) deficiency accelerate cardiac and vascular hypertrophy, dysfunction, and hypertension in response to short-term angiotensin II infusion in mice?
Answers are grounded in this paper and cite their sources.
Gpx1 deficiency accelerates angiotensin II-induced cardiac hypertrophy and left ventricular systolic dysfunction independently of blood pressure and vascular remodeling, highlighting a protective role for Gpx1 against myocardial oxidative stress.
Glutathione peroxidase 1 (Gpx1) plays an important role in cellular defense by converting hydrogen peroxide and organic hydroperoxides to nonreactive products, and Gpx1(-/-) mice, which are characterized by reduced tissue glutathione peroxidase activity, are known to exhibit enhanced oxidative stress. Peroxides participate in tissue injury, as well as the hypertrophy of cultured cells, yet the role of Gpx1 to prevent end organ damage in cardiovascular tissue is not clear. We postulated that Gpx1 deletion would potentiate both aortic and cardiac hypertrophy, as well as mean arterial blood pressure, in response to angiotensin II (AngII). Our results show that short-term AngII markedly increased left ventricular mass, myocyte cross-sectional area, and interventricular septum thickness and decreased shortening fraction in Gpx1(-/-) mice as compared with wild-type animals. On the other hand, AngII resulted in a similar increase in mean arterial blood pressure in wild-type and Gpx1(-/-) mice. Collagen deposition increased in response to AngII, but no differences were found between strains. Vascular hypertrophy increased to the same extent in Gpx1(-/-) and wild-type mice. Collectively, our results indicate that Gpx1 deficiency accelerates cardiac hypertrophy and dysfunction but has no effect on vascular hypertrophy and mean arterial blood pressure and suggest a major role for Gpx1 in cardiac dysfunction in AngII-dependent hypertension.
No takes yet. Share an insight, caveat, or question.
Ardanaz et al. (2009) studied Angiotensin II-induced hypertension and cardiac hypertrophy. Gpx1 deletion with subcutaneous Angiotensin II infusion vs. Wild-type C57Bl/6J mice and vehicle infusion was evaluated on Total heart weight to body weight ratio (THW/BW) and left ventricular shortening fraction (SF) (p=<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: